Five high-value biotech stocks to watch

Our new On the Radar report returns with fresh insights from Simos Simeonidis, PhD, Rodman & Renshaw's senior biotech analyst, who highlights biotech stocks which he believes will be good value plays in the months ahead. One reason Simeonidis is focusing on value, he explains, is that there are fewer catalyst-driven stories looming in his universe, "while I find myself speaking to investors more about value, especially given the uncertainty of the markets." In the mood for some market risk analysis? Then check out these five companies. Biotech stocks to watch >>

Suggested Articles

The deal comes almost two years after Roche dropped the tumor microenvironment modulator after putting it through a clutch of early-phase studies.

The buzzy life sciences company Verily is looking to speed up COVID testing with a new lab based at its native South San Francisco.

Although Genfit canned its NASH program last month, it has been plugging away at a blood-based diagnostic for the liver disease.